David Margolis’s laboratory has a long history of translational HIV research involving samples donated by HIV-infected volunteers: investigating basic molecular, virological, and immunological phenomenon, and leveraging insights to develop new interventions in HIV disease. Dr. Margolis has studied molecular mechanisms in HIV replication and infection, HIV proviral latency, and defined the role of epigenetic factors in the repression of HIV transcription. He has led diverse, multidisciplinary collaborations that resulted in discovery and publication of high-impact work. He is the principal investigator for CARE (Collaboratory of AIDS Researchers for Eradication), a major new NIH-funded research organization that seeks to develop the tools to bring an HIV cure from the bench to the clinic.
At the completion of this educational session, learners will:
- Be aware of current approaches to HIV eradication.
- Appreciate scientific challenges and unknowns in efforts toward the goal of eradication.
- Understand clinical and ethical challenges in this field.
This CME activity was approved for AMA PRA Category 1 Credit™
on August 19, 2014 and will terminate August, 2017.
The target audience is all physicians, NPs and PAs involved or interested in HIV education.
This online video and post-activity evaluation are one hour in length.
After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz.
You must achieve at least 70% correct to receive your CME certificate.
If successful, you will be provided instructions to print your CME certificate at the completion of this activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™
. Physicians should claim only the credit commensurate with extent of their participation in the activity.
Policies and standards of MSSNY require that speakers and planners for CME activities disclose any relevant financial relationships they may have with commercial interests whose products, devices or services may be discussed in the content of a CME activity.
Dr. James Braun (Planner/Course Director) had no relevant financial relationships to disclose.
Dr. Margolis (Presenter) had the following personal financial relationships in the pprior 12 months with manufacturers of the products or services that may be presented in this CME activity: Consulting with Chimerix, GlaxoSmithKline, and Merck; contracted research with Argos; common stock of Abbott, AbbVie, and Gilead. Dr. Margolis supported his presentation and clinical recommendations with the best available evidence from the medical literature, and submitted his slides in advance for adequate peer review.
This PRN CME activity is funded in part by unrestricted educational grants from:
Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck & Co, and ViiV Healthcare.
To obtain CME credit for this PRN program, please follow this link to the PRN Courses page
at the Clinical Education Initiative (CEI) web site. PRN and the Medical Society of the State of New York (MSSNY) jointly sponsor PRN enduring materials for CME, and provide them at no cost to the AIDS Institute of the New York State Department of Health (NYSDOH) for broadcast through the CEI. We thank the NYSDOH for making our CME programs available to a wider audience, and hope you will also browse the many other educational opportunities offered by the CEI.